- Home
- NVRI vs ANAB Comparison
NVRI vs ANAB Comparison
Compare NVRI & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVRI
- ANAB
- Stock Information
- Founded
- NVRI 1853
- ANAB 2005
- Country
- NVRI United States
- ANAB United States
- Employees
- NVRI N/A
- ANAB N/A
- Industry
- NVRI Diversified Commercial Services
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- NVRI Miscellaneous
- ANAB Health Care
- Exchange
- NVRI Nasdaq
- ANAB Nasdaq
- Market Cap
- NVRI 750.9M
- ANAB 759.5M
- IPO Year
- NVRI N/A
- ANAB 2017
- Fundamental
- Price
- NVRI $7.25
- ANAB $18.59
- Analyst Decision
- NVRI Hold
- ANAB Buy
- Analyst Count
- NVRI 1
- ANAB 12
- Target Price
- NVRI $10.00
- ANAB $41.20
- AVG Volume (30 Days)
- NVRI 645.5K
- ANAB 1.4M
- Earning Date
- NVRI 02-20-2025
- ANAB 03-10-2025
- Dividend Yield
- NVRI N/A
- ANAB N/A
- EPS Growth
- NVRI N/A
- ANAB N/A
- EPS
- NVRI N/A
- ANAB N/A
- Revenue
- NVRI $2,342,645,000.00
- ANAB $57,172,000.00
- Revenue This Year
- NVRI $16.47
- ANAB $229.13
- Revenue Next Year
- NVRI N/A
- ANAB N/A
- P/E Ratio
- NVRI N/A
- ANAB N/A
- Revenue Growth
- NVRI 13.21
- ANAB 282.17
- 52 Week Low
- NVRI $6.57
- ANAB $12.21
- 52 Week High
- NVRI $12.79
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- NVRI 25.67
- ANAB 55.28
- Support Level
- NVRI $6.99
- ANAB $12.21
- Resistance Level
- NVRI $9.30
- ANAB $21.57
- Average True Range (ATR)
- NVRI 0.37
- ANAB 1.72
- MACD
- NVRI -0.25
- ANAB 0.39
- Stochastic Oscillator
- NVRI 10.20
- ANAB 68.16
About NVRI Enviri Corporation
Enviri Corp engages in providing a broad range of environmental services and related solutions. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company serves a diverse customer base by offering critical recycle and reuse solutions for their waste streams, enabling customers to address their complex environmental challenges.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).